pyrazines has been researched along with Autoimmune Diabetes in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB | 1 |
| Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E | 1 |
| Hari Kumar, KV; Prusty, P; Shaikh, A | 1 |
| Cimburek, Z; Dovolilová, E; Saudek, F; Vargová, L; Vojtová, L; Zacharovová, K | 1 |
| Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P | 1 |
| Huang, G; Leslie, RD; Li, X; Liu, L; Long, Z; Wang, X; Xiang, Y; Yang, L; Zhao, Y; Zhou, Z | 1 |
| Ambrósio, AF; Fernandes, R; Gonçalves, A; Leal, E; Marques, C; Reis, F; Ribeiro, CF | 1 |
| Gottschalk, M; Griffin, KJ; Kyllo, JH; Rabinovitch, A; Thompson, PA | 1 |
| Kohara, N; Satoh, J; Sekiguchi, K; Yamaguchi, Y | 1 |
| Seissler, J | 1 |
| Doudet, DJ; Kim, SJ; McIntosh, CH; Nian, C | 1 |
| Bril, V; Buchanan, R; Hirose, T; Tomioka, S | 1 |
| Acerini, CL; Bluck, LJ; Dunger, DB; Humphreys, SM; Jackson, SJ; Marcovecchio, ML; Salgin, B; Williams, RM | 1 |
| Aleksunes, LM; Goedken, MJ; Klaassen, CD; Reisman, SA; Yeager, RL | 1 |
| Barth, RN; Cooper, M; Gurk-Turner, C; Hurley, H; KuKuruga, D; Manitpisitkul, W; Philosophe, B; Rasetto, F; Wilson, N | 1 |
| Bloom, D; Djamali, A; Lorentzen, D; Mezrich, JD; Miller, KM; Muth, BL; Pirsch, JD; Sollinger, HW; Torrealba, J | 1 |
| Ellis, SL; Garg, SK; Hazenfield, RM; Moser, EG; Rodionova, AS; Snell-Bergeon, JK | 1 |
| Gupta, S | 1 |
| Caldeira, EJ; da Silva Faria, AL; da Silva, RE; Dias, MA; Ferreira Junior, RS; Leme, VB; Mâncio, RD; Mayoral, EE | 1 |
| Bax, JJ; Bountioukos, MA; Elhendy, A; Krenning, EP; Poldermans, D; Roelandt, JR; Schinkel, AF; Valkema, R; van Domburg, RT; Vourvouri, EC | 1 |
| Alvarez, P; Casanueva, FF; Cordido, F; Dieguez, C; Isidro, L; Leal-Cerro, A; Peinó, R | 1 |
| Bril, V; Buchanan, RA | 2 |
| Campbell, KM; Taylor, JR | 1 |
| Fazio, F; Landoni, C; Lucignani, G; Monti, LD; Moresco, RM; Piatti, P; Pozza, G; Stefani, I | 1 |
| Bolli, GB; Brunetti, P; Ciofetta, M; Di Vincenzo, A; Epifano, L; Fanelli, C; Lepore, M; Modarelli, F; Pampanelli, S | 1 |
| Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD | 1 |
| Baum, RP; Hertel, A; Hör, G; Schröder, O | 1 |
3 review(s) available for pyrazines and Autoimmune Diabetes
| Article | Year |
|---|---|
Type 1 diabetes and cardiovascular disease.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Immunotherapies in diabetes mellitus type 1.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Azathioprine; Basiliximab; Chaperonin 60; Cyclosporine; Daclizumab; Diabetes Mellitus, Type 1; Diet; Etanercept; Exenatide; Fatty Acids, Unsaturated; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Insulin; Interferon-alpha; Interleukin 1 Receptor Antagonist Protein; Islets of Langerhans Transplantation; Niacinamide; Peptide Fragments; Peptides; Primary Prevention; Pyrazines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rituximab; Secondary Prevention; Sitagliptin Phosphate; Tertiary Prevention; Triazoles; Venoms; Vitamin D; Vitamins | 2012 |
Diabetes drug update: how 4 new options stack up.
Topics: Administration, Inhalation; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Exenatide; Family Practice; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Islet Amyloid Polypeptide; Male; Peptides; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2007 |
14 trial(s) available for pyrazines and Autoimmune Diabetes
| Article | Year |
|---|---|
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
Topics: Adult; Diabetes Mellitus, Type 1; Exenatide; Female; Humans; Insulin; Male; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Young Adult | 2013 |
Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lansoprazole; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; United States | 2014 |
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
Topics: Administration, Oral; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Japan; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Motor Neurons; Neural Conduction; Pyrazines; Sensory Receptor Cells; Severity of Illness Index; Spiro Compounds; Temperature | 2016 |
Ranirestat for the management of diabetic sensorimotor polyneuropathy.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Median Nerve; Middle Aged; Motor Neurons; Neural Conduction; Placebos; Pyrazines; Sensory Thresholds; Spiro Compounds; Sural Nerve; Young Adult | 2009 |
Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Female; Human Growth Hormone; Humans; Insulin Resistance; Male; Pyrazines | 2009 |
Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles; United States | 2011 |
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.
Topics: Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Male; Middle Aged; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Ventricular Dysfunction, Left | 2003 |
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electromyography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Probability; Pyrazines; Reference Values; Risk Assessment; Severity of Illness Index; Spiro Compounds; Sural Nerve; Treatment Outcome | 2004 |
Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Motor Neurons; Neural Conduction; Patient Selection; Peripheral Nerves; Peroneal Nerve; Placebos; Pyrazines; Spiro Compounds; Sural Nerve | 2006 |
Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels.
Topics: Adult; Biological Transport, Active; Deoxyglucose; Diabetes Mellitus, Type 1; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Fluorodeoxyglucose F18; Glucose; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Insulin; Male; Myocardium; Pyrazines; Somatostatin; Tomography, Emission-Computed | 1995 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides | 1999 |
Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results.
Topics: Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Clamp Technique; Heart; Humans; Hyperinsulinism; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pyrazines; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 1998 |
11 other study(ies) available for pyrazines and Autoimmune Diabetes
| Article | Year |
|---|---|
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Topics: A549 Cells; Amides; Antiviral Agents; Azithromycin; Benzimidazoles; Coxsackievirus Infections; Diabetes Mellitus, Type 1; Drug Repositioning; Enterovirus B, Human; Fluoxetine; Guanidine; Humans; Immunoglobulin G; Lovastatin; Oxadiazoles; Oxazoles; Oximes; Pyrazines; Ribavirin; Sulfonamides | 2020 |
The effects of DPP-IV inhibition in NOD mice with overt diabetes.
Topics: Animals; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Islets of Langerhans; Lymph Nodes; Mice; Mice, Inbred NOD; Pyrazines; Sitagliptin Phosphate; Spleen; T-Lymphocyte Subsets; Time Factors; Triazoles | 2013 |
Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Topics: Animals; Apoptosis; Biomarkers; Blood-Retinal Barrier; Blotting, Western; Cell Death; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme-Linked Immunosorbent Assay; Immunoenzyme Techniques; Inflammation; Male; Neurons; Pyrazines; Rats; Rats, Wistar; Retina; Sitagliptin Phosphate; Triazoles | 2014 |
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin | 2008 |
Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.
Topics: Animals; Diabetes Mellitus, Type 1; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Graft Rejection; Graft Survival; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred NOD; Pyrazines; Sitagliptin Phosphate; T-Lymphocytes; Transplantation, Isogeneic; Triazoles | 2009 |
Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose Intolerance; Glucose-6-Phosphatase; Hyperglycemia; Insulin; Liver; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Pancreas; Phosphoenolpyruvate Carboxykinase (GTP); Pyrazines; Pyruvate Kinase; RNA, Messenger; Thiones; Thiophenes; Urodynamics | 2010 |
Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
Topics: Adult; Antilymphocyte Serum; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Graft Rejection; Histocompatibility Testing; HLA Antigens; Humans; Isoantibodies; Kidney Failure, Chronic; Kidney Transplantation; Male; Pancreas Transplantation; Plasmapheresis; Protease Inhibitors; Pyrazines; Renal Dialysis; Reoperation; Tissue Donors; Treatment Outcome | 2009 |
Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.
Topics: Acute Disease; Adult; Boronic Acids; Bortezomib; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diuresis; Drug Resistance, Multiple; Graft Rejection; Humans; Immunization; Kidney Transplantation; Male; Pancreas Transplantation; Protease Inhibitors; Pyrazines | 2009 |
Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice.
Topics: Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Extracellular Matrix; Female; Homeostasis; Hypoglycemic Agents; Mice; Mice, Inbred NOD; Microscopy, Polarization; Pyrazines; Salivary Glands; Sitagliptin Phosphate; Triazoles | 2013 |
Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Topics: Adult; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypolipidemic Agents; Male; Pyrazines; Somatomedins | 2003 |
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Brain; Cognition; Diabetes Mellitus, Type 1; Female; Glycerol; Homeostasis; Hormones; Humans; Hydroxybutyrates; Hypoglycemia; Hypolipidemic Agents; Insulin; Insulinoma; Ketone Bodies; Lactates; Lipolysis; Male; Pancreatic Neoplasms; Pyrazines; Reaction Time | 1993 |